Stripe publishes a restricted businesses list — the categories it won't serve. Research chemicals and unapproved or investigational substances sit within it, and research peptides fall inside that scope.
That policy is public, and it hasn't changed in any way that helps. What confuses founders isn't the policy. It's that you can sign up anyway.
Why you got approved anyway
Stripe's onboarding is automated by design — that's the product. You enter business details, select a category from a dropdown, and you're processing within minutes. It's genuinely excellent for the businesses it's built for.
But that approval is not underwriting. No human reviewed your website when you signed up. You self-selected a category, and the system took it.
Underwriting happens later, and it's triggered by ordinary events:
- Processing volume crossing a threshold
- A cluster of chargebacks or refunds
- A customer complaint or support escalation
- An inquiry from a partner bank
- A periodic sweep of a merchant category
- Manual review prompted by something on your site
The gap between signup and review is what makes this dangerous. Months of successful processing feel like confirmation you're in the clear. They're not evidence of anything except that nobody has looked yet.
- Research peptides fall within Stripe's restricted-business scope. Instant approval is not underwriting.
- Review is triggered by growth — which means enforcement tends to land during your best month, not your worst.
- The typical outcome is payouts stopped, balance held 90–180 days, account closed — and sometimes a MATCH listing.
- Selecting a softer category on the application is a material misrepresentation to a financial institution, and it's what turns a closure into a full-length hold.
- The alternatives are a properly underwritten high-risk account, or inquiry-based ordering with no public checkout.
What happens when the review lands
The sequence is consistent enough to describe:
- Payouts stop. Usually the first visible sign — settlements simply don't arrive.
- A notice arrives, typically citing a policy section rather than explaining specifics.
- The balance is held against refunds and chargebacks that may still come in against transactions already processed. Commonly 90–180 days.
- The account is closed.
- Possibly a MATCH listing — the card networks' database of terminated merchants, checked by acquirers during underwriting, which typically persists for five years.
The timing is the cruel part. Because review is triggered by volume and disputes, enforcement correlates with growth. Brands lose access to their money during their best month, holding supplier invoices they can no longer pay.
The category-selection trap
Here's where founders make the decision that determines how badly this goes.
Facing a dropdown with no accurate option, many pick something adjacent — "supplements", "health and wellness", "laboratory supplies", "nutraceuticals". Sometimes it's deliberate. Often it's someone choosing the least-wrong option in a form that doesn't have a right one, and never thinking about it again.
There's a practical argument here as well as an ethical one, pointing the same way. An underwriter who knows you sell research peptides and approves you anyway cannot later "discover" it. There is nothing to find. That's precisely what you're paying the higher rate for.
The other aggregators
The specifics differ; the outcome doesn't.
| Provider | Practical position for research peptides |
|---|---|
| Stripe | Restricted businesses list covers research chemicals and unapproved substances. |
| PayPal | Acceptable use policy restricts this territory; account holds are common and can be lengthy. |
| Square | Prohibited goods and services list covers comparable ground. |
| Shopify Payments | Prohibited business list covers the category — and Shopify's platform policy separately restricts what you can list at all. |
That last row is worth emphasising because founders conflate the two. Shopify has two separate policies: one governing payments and one governing the platform. Bringing your own high-risk gateway addresses the first and does nothing about the second — you can be fully approved by an underwriter and still have the store removed. See can you sell peptides on Shopify.
What to use instead
A high-risk merchant account. A processor that underwrites research peptides deliberately, working with a sponsor bank comfortable with the category. Higher effective rates, real documentation requirements, and a reserve — in exchange for an approval that nobody reverses because there's nothing left to discover. High-risk peptide merchant accounts covers underwriting, documents and reserve terms.
Inquiry-based ordering. No public card checkout at all. Researchers request a quote, you review the account and invoice. It adds friction and slows the funnel, but there's no processor sitting on your storefront to freeze. The public site still has crawlable product and category pages, so the SEO still works. See the inquiry-based ordering model.
Many mature brands run both — an underwritten account for standard orders and an inquiry path for larger volume.
If you're processing on Stripe right now
Don't panic, and don't wait either.
- Assume review is a matter of time, not chance. Plan on that basis.
- Don't let the balance build. The larger your held balance when review lands, the worse the outcome.
- Start the properly underwritten application now, in parallel. Approval takes days to weeks; you want it live before you need it.
- Fix the storefront first. Compliance drift, missing policies and thin contact details will decline your next application too. Underwriters read websites.
- Export your data regularly. Transactions, customers, payouts. Don't be reconstructing records after access is revoked.
- Have an inquiry path ready. Even as a stopgap, it keeps revenue moving if card processing stops abruptly.
The takeaway
Stripe's position on this category is public and unambiguous. The confusion comes entirely from automated onboarding, which lets you start processing long before anyone assesses whether you should be.
Treating that gap as permission is the single most expensive mistake available to a research-peptide founder — and choosing a softer category on the application to widen the gap is what turns a manageable account closure into a six-month hold on everything you've earned.
Go get underwritten properly, describe the business accurately, and pay the higher rate. It's the boring answer and it's the one that's still working in year two.